Immuneering Raises $62m in Series B Round
19 Jan 2021
Immuneering has raised $62m in an oversubscribed Series B round led by high-profile life science investors.
NewAmsterdam Pharma Completes $196M (€160M) Series A Funding for Comprehensive Phase 3 Development Program
14 Jan 2021
Founding investor Forbion joined by co-lead investors, Morningside Ventures and Ascendant BioCapital, and other leaders in global biopharmaceutical investment.
Join Our Newsletter for Free
